Loading clinical trials...
Loading clinical trials...
Phase II Study of FGFR Inhibitor Futibatinib in Combination With Anti-PD-1 Antibody Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma With FGF19 Expression After First Line Therapy
Conditions
Interventions
Futibatinib
Pembrolizumab
+1 more
Locations
1
United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Start Date
August 17, 2021
Primary Completion Date
September 18, 2024
Completion Date
August 31, 2025
Last Updated
November 18, 2025
NCT05969860
NCT06427941
NCT06066138
NCT06811116
NCT07174570
NCT07039201
Lead Sponsor
Mayo Clinic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions